Literature DB >> 12199790

Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide.

Je-Hwan Lee1, Kyoo-Hyung Lee, Jung-Hee Lee, Shin Kim, Miee Seol, Chan-Jeoung Park, Hyun-Sook Chi, Weechang Kang, Seung Taik Kim, Woo-Kun Kim, Jung-Shin Lee.   

Abstract

We attempted to identify the diagnostic markers and severity predictors of hepatic veno-occlusive disease (VOD) in 115 adult patients who were uniformly conditioned with busulphan and cyclophosphamide and who underwent allogeneic bone marrow transplantation (BMT). A diagnosis of VOD was made according to clinical criteria. Severity of VOD was classified as mild, moderate or severe. Various haemostatic parameters were determined at five time points (d -7, 0, 7, 14 and 21). Using clinical and haemostatic parameters, we developed multivariate models to identify diagnostic markers as well as severity predictors of VOD. Of the 115 patients included in the study, 50 (43.5%) developed VOD. Twenty-nine had mild VOD, 13 moderate and 8 severe. Multiple logistic regression models showed that plasminogen activator inhibitor-1 (PAI-1) antigen (P = 0.029), percentage change of body weight (P = 0.001) and bilirubin (P < 0.001) were independent marker variables for the occurrence of VOD, and PAI-1 antigen (P = 0.030) and bilirubin (P = 0.049) were independent marker variables for the occurrence of severe VOD. Our study suggests that PAI-1 antigen can be used as a diagnostic marker as well as a severity predictor of VOD after allogeneic BMT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12199790     DOI: 10.1046/j.1365-2141.2002.03748.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Prophylactic Effect of Recombinant Human Soluble Thrombomodulin for Hepatic Sinusoidal Obstruction Syndrome Model Mice.

Authors:  Shunsuke Kanou; Tomoharu Miyashita; Yasuhiko Yamamoto; Satoshi Takada; Makoto Nakura; Mitsuyoshi Okazaki; Yoshinao Ohbatake; Shinichi Nakanuma; Isamu Makino; Hidehiro Tajima; Hiroyuki Takamura; Sachio Fushida; Tetsuo Ohta
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

3.  PAI-1 antagonists: the promise and the peril.

Authors:  Douglas E Vaughan
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

4.  Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis.

Authors:  Layton H Smith; John D Dixon; John R Stringham; Mesut Eren; Hassan Elokdah; Dave L Crandall; Kay Washington; Douglas E Vaughan
Journal:  Blood       Date:  2005-09-13       Impact factor: 22.113

Review 5.  Biomarkers for Early Complications After Hematopoietic Stem Cell Transplantation.

Authors:  Courtney M Rowan; Sophie Paczesny
Journal:  Clin Lab Med       Date:  2018-12-18       Impact factor: 1.935

Review 6.  Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation.

Authors:  Erden Atilla; Pınar Ataca Atilla; Güldane Cengiz Seval; Mehmet Bektaş; Taner Demirer
Journal:  Turk J Gastroenterol       Date:  2019-02       Impact factor: 1.852

Review 7.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Authors:  Jason A Coppell; Paul G Richardson; Robert Soiffer; Paul L Martin; Nancy A Kernan; Allen Chen; Eva Guinan; Georgia Vogelsang; Amrita Krishnan; Sergio Giralt; Carolyn Revta; Nicole A Carreau; Massimo Iacobelli; Enric Carreras; Tapani Ruutu; Tiziano Barbui; Joseph H Antin; Dietger Niederwieser
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-18       Impact factor: 5.742

8.  Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes.

Authors:  K Yakushijin; Y Atsuta; N Doki; A Yokota; H Kanamori; T Miyamoto; C Ohwada; K Miyamura; Y Nawa; M Kurokawa; I Mizuno; T Mori; M Onizuka; J Taguchi; T Ichinohe; H Yabe; Y Morishima; K Kato; R Suzuki; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

9.  Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.

Authors:  Paul G Richardson; Vincent T Ho; Sergio Giralt; Sally Arai; Shin Mineishi; Corey Cutler; Joseph H Antin; Nicole Stavitzski; Dietger Niederwieser; Ernst Holler; Enric Carreras; Robert Soiffer
Journal:  Ther Adv Hematol       Date:  2012-08

10.  Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.

Authors:  Corey Cutler; Kristen Stevenson; Haesook T Kim; Paul Richardson; Vincent T Ho; Erica Linden; Carolyn Revta; Ruth Ebert; Diane Warren; Sung Choi; John Koreth; Philippe Armand; Edwin Alyea; Shelly Carter; Mary Horowitz; Joseph H Antin; Robert Soiffer
Journal:  Blood       Date:  2008-09-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.